Guardant Health, Inc. GH stock is trading higher on Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the company’s Shield multi-cancer detection (MCD) test.The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types, including bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer.At the 2025 American Soc ...